Aliskiren/amlodipine explained

The drug combination aliskiren/amlodipine (INNs, trade names Tekamlo and Rasilamlo) is an antihypertensive. Clinical trials have shown it to be more effective than amlodipine on its own,^[1] with a high dosing regime (aliskiren 300 mg/amlodipine 10 mg) being more effective than olmesartan/amlodipine with comparable tolerability.^[2]

Further reading

• Web site: FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna) . . 19 January 2016 .

External links

• Web site: Aliskiren mixture with amlodipine . U.S. National Library of Medicine. Drug Information Portal .

Notes and References

1. Pfeiffer D, Rennie N, Papst CC, Zhang J . Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥ . Current Vascular Pharmacology . 10 . 6 . 773–80 . November 2012 . 22303911 . 10.2174/157016112803520945 .
2. Axthelm C, Sieder C, Meister F, Kaiser E . Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg . Current Medical Research and Opinion . 28 . 1 . 69–78 . January 2012 . 22117838 . 10.1185/03007995.2011.637914 . 25693979 .